Arkolith/Insider Trading/SPRY/Form 4

Lowenthal Richard E

PRESIDENT AND CEO, Director, 10% OwnerARS Pharmaceuticals, Inc. (SPRY) · full profile →Form 4 · filed Aug 22, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$725K
Net Open-Market Flow
-$725K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 21, 2025Sell(S)50K$14.49$725K1.2M

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-022761) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML